Evidence map›Paper›PMID 42569136›Full record

ReviewPolish journal of radiology2026

The role of magnetic resonance imaging (MRI) in breast cancer molecular subtypes.

Run Xu, Zeyang Miao, Xiaoyong Zuo, Li Lu, Peng Luo, Guanwu Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Polish journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Run XuYueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zeyang MiaoYueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Xiaoyong ZuoYueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Li LuYueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Peng LuoYueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Guanwu LiYueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer heterogeneity is crucial for treatment decision-making and prognosis prediction. Magnetic resonance imaging (MRI) is a key tool in breast imaging, providing a non-invasive assessment of morphological characteristics, cell density, hemodynamics, and vascular proliferation. Integrating MRI with advanced techniques such as radiomics, habitat imaging, and artificial intelligence enables a deeper understanding of tumor morphology and biological behavior through analysis of imaging features, thereby characterizing the heterogeneity inherent in breast cancer. This review explores MRI's role as an imaging biomarker for evaluating breast cancer molecular subtypes, aiming to support personalized treatment strategies and improve therapeutic outcomes.

Indexed as

breast cancerhabitat imagingheterogeneitymagnetic resonance imagingmolecular subtyperadiomics

Identifiers

PMID42569136
PMCPMC13449062

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.